Physician profile
Benjamin Daniel Wind
NPI 1831279488
$167,946.90
in general payments reported to CMS, 2019-2025
31 companies · $45K in 2025
The $45K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $267 · 2021: $378 · 2022: $20K · 2023: $44K · 2024: $58K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $116K · Consulting Fee: $13K · Travel and Lodging: $9,486 · Food and Beverage: $7,806 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $116,280.00 |
| Consulting Fee | $12,700.00 |
| Travel and Lodging | $9,486.04 |
| Food and Beverage | $7,805.74 |
| Education | $141.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $76,920.73 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| United Therapeutics Corporation | $73,243.45 | 2021-2025 | Tyvaso, Orenitram, Remodulin |
| Bayer Healthcare Pharmaceuticals INC. | $14,994.13 | 2019-2024 | |
| Glaxosmithkline, LLC. | $466.13 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $333.34 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Merck Sharp & Dohme LLC | $258.85 | 2019-2025 | Winrevair |
| Insmed, INC. | $226.40 | 2019-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.54 | 2019-2025 | Jascayd |
| Mylan Specialty L.P. | $147.93 | 2019-2020 | |
| Pulmonx Corporation | $142.56 | 2023 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Alnylam Pharmaceuticals INC. | $122.88 | 2023 | Amvuttra |
| Philips North America LLC | $121.21 | 2019 | |
| Grifols USA, LLC | $89.26 | 2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $86.91 | 2019-2020 | |
| Amgen INC. | $71.31 | 2022-2024 | Tezspire |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $69.66 | 2019-2020 | |
| Electromed, INC. | $58.73 | 2019-2025 | Smartvest |
| Verona Pharma, INC. | $52.10 | 2025 | Ohtuvayre |
| Baxter Healthcare | $42.89 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Sandoz INC. | $38.95 | 2023 | Treprostinil |
| Teva Pharmaceuticals USA, INC. | $35.35 | 2019 | |
| Genzyme Corporation | $33.70 | 2019-2020 | |
| Harmony Biosciences LLC | $28.67 | 2025 | |
| Pfizer INC. | $27.13 | 2019-2020 | |
| Lilly USA, LLC | $23.44 | 2025 | Mounjaro, Zepbound |
| Ani Pharmaceuticals, INC. | $20.98 | 2025 | Purified Cortrophin Gel |
| Sanofi Pasteur INC. | $15.48 | 2020 | |
| Amarin Pharma, INC. | $15.29 | 2019 | |
| Bridgebio Pharma, INC. | $13.50 | 2025 | Attruby |
| Novo Nordisk INC | $13.09 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Wind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.